India’s First Dengue Vaccine Expected to Arrive in 2027

Bangla Press Desk: India could soon have an additional tool to fight dengue, a mosquito-borne viral disease that affects large parts of the country, particularly during and after the monsoon season.

Dr Reddy’s Laboratories has signed an agreement with Japanese drugmaker Takeda Pharmaceutical to promote and distribute Takeda’s Qdenga dengue vaccine in India, India Today reports.The vaccine is expected to become available in the first half of 2027, following regulatory and market authorisation processes.

The development comes at a time when dengue continues to remain a public health concern in India. The disease is mainly transmitted by Aedes mosquitoes, which can breed in stagnant water. Seasonal outbreaks can put pressure on hospitals and healthcare systems, making prevention an important part of dengue control.

What is Qdenga?

Qdenga is a dengue vaccine developed by Takeda Pharmaceutical. According to the source, it is designed to protect against all four dengue virus serotypes and is intended for children and adults between four and 60 years of age.

The vaccine is administered as two injections of 0.5 ml each, with the second dose given three months after the first. One feature of the vaccine is that it can be given regardless of whether a person has previously been exposed to dengue, meaning pre-vaccination testing is not required.

When will the dengue vaccine be available in India?

The vaccine is expected to be available in India during the first half of 2027. However, its availability will follow the necessary regulatory and market authorisation processes.

Qdenga received approval from India’s drug regulator in July 2026, according to the source. The agreement between Dr Reddy’s Laboratories and Takeda will allow the vaccine to be promoted and distributed in the Indian market.

How effective is the vaccine?

The vaccine has shown protection against confirmed dengue infections. The source states that Qdenga showed 80.2% efficacy against confirmed dengue cases one year after the second dose in a late-stage trial.The vaccine is expected to become available in the first half of 2027, following regulatory and market authorisation processes.

The development comes at a time when dengue continues to remain a public health concern in India. The disease is mainly transmitted by Aedes mosquitoes, which can breed in stagnant water. Seasonal outbreaks can put pressure on hospitals and healthcare systems, making prevention an important part of dengue control.

What is Qdenga?

Qdenga is a dengue vaccine developed by Takeda Pharmaceutical. According to the source, it is designed to protect against all four dengue virus serotypes and is intended for children and adults between four and 60 years of age.

The vaccine is administered as two injections of 0.5 ml each, with the second dose given three months after the first. One feature of the vaccine is that it can be given regardless of whether a person has previously been exposed to dengue, meaning pre-vaccination testing is not required.

When will the dengue vaccine be available in India?

The vaccine is expected to be available in India during the first half of 2027. However, its availability will follow the necessary regulatory and market authorisation processes.

Qdenga received approval from India’s drug regulator in July 2026, according to the source. The agreement between Dr Reddy’s Laboratories and Takeda will allow the vaccine to be promoted and distributed in the Indian market.

How effective is the vaccine?

The vaccine has shown protection against confirmed dengue infections. The source states that Qdenga showed 80.2% efficacy against confirmed dengue cases one year after the second dose in a late-stage trial.